dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Wick, Antje |
dc.contributor.author | Desjardins, Annick |
dc.contributor.author | Suárez Rodríguez, Cristina |
dc.contributor.author | Forsyth, Peter |
dc.contributor.author | Gueorguieva, Ivelina |
dc.contributor.author | Burkholder, Tiana |
dc.contributor.author | Rodon Ahnert, Jordi |
dc.date.accessioned | 2021-10-26T07:19:31Z |
dc.date.available | 2021-10-26T07:19:31Z |
dc.date.issued | 2020-10 |
dc.identifier.citation | Wick A, Desjardins A, Suarez C, Forsyth P, Gueorguieva I, Burkholder T, et al. Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. Invest New Drugs. 2020 Oct;38:1570–1579. |
dc.identifier.issn | 1573-0646 |
dc.identifier.uri | https://hdl.handle.net/11351/6463 |
dc.description | Biomarcadors; Glioblastoma; Radioqimioteràpia |
dc.description.sponsorship | Open Access funding provided by Projekt DEAL. This trial was funded by Eli Lilly and Company. |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Investigational New Drugs;38 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Gliomes |
dc.subject | Cervell - Càncer - Quimioteràpia |
dc.subject | Cervell - Càncer - Radioteràpia |
dc.subject.mesh | Glioma |
dc.subject.mesh | Chemoradiotherapy |
dc.title | Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s10637-020-00910-9 |
dc.subject.decs | glioma |
dc.subject.decs | quimiorradioterapia |
dc.relation.publishversion | https://doi.org/10.1007/s10637-020-00910-9 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Wick A] Clinical Cooperation Unit Neuro-oncology, German Cancer Research Center, Heidelberg University Medical Center, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany. [Desjardins A] The Preston Robert Tisch Brain Tumor Center at Duke, Duke University, Durham, NC, USA. [Suarez C] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Forsyth P] H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. [Gueorguieva I] Eli Lilly and Company, Erl Wood, UK 6 Eli Lilly and Company, Indianapolis, IN, USA. [Burkholder T] Eli Lilly and Company, Indianapolis, IN, USA. [Rodon J] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, U. T. M. D. Anderson Cancer Center, Houston, TX, USA |
dc.identifier.pmid | 32140889 |
dc.identifier.wos | 000518298200001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |